The closing price of Diversified Healthcare Trust (NASDAQ: DHC) was $2.74 for the day, up 1.11% from the previous closing price of $2.71. In other words, the price has increased by $+0.0300 from its previous closing price. On the day, 511534 shares were traded.
Ratios:
Our analysis of DHC’s different ratios will help us gain a deeper understanding of the company. In the meantime, Its Debt-to-Equity ratio is 1.22 whereas as Long-Term Debt/Eq ratio is at 1.21.
Wells Fargo Downgraded its Overweight to Equal Weight on January 17, 2020, while the target price for the stock was maintained at $9.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 14 ’23 when PORTNOY ADAM D. bought 2,000,000 shares for $3.07 per share. The transaction valued at 6,132,600 led to the insider holds 23,250,019 shares of the business.
PORTNOY ADAM D. bought 1,992,259 shares of DHC for $6,026,783 on Jun 13 ’23. The Director now owns 21,250,019 shares after completing the transaction at $3.03 per share. On Jun 12 ’23, another insider, PORTNOY ADAM D., who serves as the Director of the company, bought 2,011,256 shares for $2.87 each. As a result, the insider paid 5,778,540 and bolstered with 19,257,760 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DHC now has a Market Capitalization of 658.75M and an Enterprise Value of 3.23B. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.26 while its Price-to-Book (P/B) ratio in mrq is 0.28. Its current Enterprise Value per Revenue stands at 2.29 whereas that against EBITDA is 15.89.
Stock Price History:
Over the past 52 weeks, DHC has reached a high of $3.96, while it has fallen to a 52-week low of $0.80. The 50-Day Moving Average of the stock is 2.7440, while the 200-Day Moving Average is calculated to be 2.5602.
Shares Statistics:
DHC traded an average of 1.29M shares per day over the past three months and 889.5k shares per day over the past ten days. A total of 240.42M shares are outstanding, with a floating share count of 215.61M. Insiders hold about 10.32% of the company’s shares, while institutions hold 76.09% stake in the company. Shares short for DHC as of Mar 15, 2024 were 7.86M with a Short Ratio of 6.07, compared to 4.89M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 3.27% and a Short% of Float of 3.69%.
Dividends & Splits
With its trailing 12-month dividend rate of 0.04, DHC has a forward annual dividend rate of 0.04. Against a Trailing Annual Dividend Yield of 1.48%, it implies a Forward Annual Dividend Yield of 1.66%. The stock’s 5-year Average Dividend Yield is 5.35.
Earnings Estimates
The firm’s stock currently is rated by 1 analysts. On average, analysts expect EPS of -$0.28 for the current quarter, with a high estimate of -$0.28 and a low estimate of -$0.28, while EPS last year was -$0.27. The consensus estimate for the next quarter is -$0.27, with high estimates of -$0.27 and low estimates of -$0.27.
Analysts are recommending an EPS of between -$1.05 and -$1.05 for the fiscal current year, implying an average EPS of -$1.05. EPS for the following year is -$0.76, with 1 analysts recommending between -$0.76 and -$0.76.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 3 analysts. It ranges from a high estimate of $372.9M to a low estimate of $367.62M. As of the current estimate, Diversified Healthcare Trust’s year-ago sales were $337.61M, an estimated increase of 9.80% from the year-ago figure.
A total of 3 analysts have provided revenue estimates for DHC’s current fiscal year. The highest revenue estimate was $1.53B, while the lowest revenue estimate was $1.5B, resulting in an average revenue estimate of $1.51B. In the same quarter a year ago, actual revenue was $1.41B, up 7.40% from the average estimate. Based on 3 analysts’ estimates, the company’s revenue will be $1.61B in the next fiscal year. The high estimate is $1.64B and the low estimate is $1.58B. The average revenue growth estimate for next year is up 6.30% from the average revenue estimate for this year.
